Romosozumab-Aqqg

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology.

Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology.

Journal: Aging clinical and experimental research

Published: March 13, 2026

A bone optimization rheumatology clinic increases anabolic bone agent use and reduces mechanical complications in adult spinal deformity surgery.

A bone optimization rheumatology clinic increases anabolic bone agent use and reduces mechanical complications in adult spinal deformity surgery.

Journal: Spine deformity

Published: September 04, 2025

Comparison table: Some drugs for postmenopausal osteoporosis.

Comparison table: Some drugs for postmenopausal osteoporosis.

Journal: The Medical letter on drugs and therapeutics

Published: July 09, 2024

Drugs for postmenopausal osteoporosis.

Drugs for postmenopausal osteoporosis.

Journal: The Medical letter on drugs and therapeutics

Published: July 09, 2024

Inhibition of both sclerostin and DKK1 results in novel skull findings in the rat and non-human primate that is not observed with inhibition of sclerostin alone.

Inhibition of both sclerostin and DKK1 results in novel skull findings in the rat and non-human primate that is not observed with inhibition of sclerostin alone.

Journal: Bone

Published: October 27, 2023

Bone union-promoting effect of romosozumab in an ovariectomized rat posterolateral lumbar fusion model.

Bone union-promoting effect of romosozumab in an ovariectomized rat posterolateral lumbar fusion model.

Journal: Journal of orthopaedic research : official publication of the Orthopaedic Research Society

Published: August 03, 2023

Loss of Nmp4 enhances bone gain from sclerostin antibody administration.

Loss of Nmp4 enhances bone gain from sclerostin antibody administration.

Journal: Bone

Published: July 05, 2023

A breakthrough in the management of postmenopausal osteoporosis with very high fracture risk : romosozumab (Evenity®), a humanized monoclonal anti-sclerostin antibody

A breakthrough in the management of postmenopausal osteoporosis with very high fracture risk : romosozumab (Evenity®), a humanized monoclonal anti-sclerostin antibody

Journal: Revue medicale de Liege

Published: April 17, 2023

Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J).

Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J).

Journal: Pharmacoepidemiology and drug safety

Published: December 08, 2022

Osteoporosis: A Review of Novel Agents.

Osteoporosis: A Review of Novel Agents.

Journal: Orthopedic nursing

Published: November 22, 2022

Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia.

Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia.

Journal: Journal of the Endocrine Society

Published: July 08, 2022

Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis.

Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Published: November 09, 2021

Showing 1-12 of 30

Last Updated: 04/28/2026